172,229 Shares in Janux Therapeutics, Inc. $JANX Acquired by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 172,229 shares of the company’s stock, valued at approximately $2,646,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Nano Cap New Millennium Growth Fund L P bought a new stake in Janux Therapeutics in the fourth quarter valued at $34,000. Versant Capital Management Inc grew its position in shares of Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after acquiring an additional 784 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Janux Therapeutics during the fourth quarter worth about $51,000. Osaic Holdings Inc. increased its holdings in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares during the period. Finally, Quantbot Technologies LP increased its holdings in shares of Janux Therapeutics by 2,290.0% in the 2nd quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock worth $84,000 after acquiring an additional 5,267 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JANX has been the subject of a number of analyst reports. Wolfe Research raised shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Monday, August 24th. Stifel Nicolaus set a $35.00 target price on shares of Janux Therapeutics in a research report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Monday, July 20th. Truist Financial reaffirmed a “buy” rating and set a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Finally, Evercore set a $22.00 price objective on Janux Therapeutics in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.46.

Janux Therapeutics Stock Performance

Shares of JANX opened at $19.70 on Thursday. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -12.01 and a beta of 2.53. Janux Therapeutics, Inc. has a one year low of $12.12 and a one year high of $35.34. The stock’s fifty day moving average is $16.38 and its 200-day moving average is $14.95.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to analyst estimates of $19.07 million. Analysts forecast that Janux Therapeutics, Inc. will post -1.76 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.